High-Efficacy Disease-Modifying Therapies in People with Relapsing–Remitting Multiple Sclerosis: The Role of Risk Attitude in Treatment Decisions

被引：0
|
作者：
Jorge Maurino
Javier Sotoca
Ángel P. Sempere
Luis Brieva
Carlos López de Silanes
Ana B. Caminero
María Terzaghi
Julia Gracia-Gil
Gustavo Saposnik
机构：
[1] Roche Farma,Medical Department
[2] Hospital Universitari Mútua de Terrassa,Department of Neurology
[3] Hospital General Universitario de Alicante,Department of Neurology
[4] Hospital Universitari Arnau de Vilanova,Department of Neurology
[5] Hospital Universitario de Torrejón,Department of Neurology
[6] Complejo Asistencial de Ávila,Department of Neurology
[7] University of Toronto,Decision Neuroscience Unit, Li Ka Shing Institute
[8] Complejo Hospitalario Universitario de Albacete,Department of Neurology
[9] University of Toronto,Division of Neurology, Department of Medicine, St. Michael’s Hospital
[10] University of Zurich,Laboratory for Social and Neural System Research, Department of Economics
来源：
The Patient - Patient-Centered Outcomes Research | 2021年 / 14卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：241 / 248
页数：7
相关论文
共 50 条
  • [1] High-Efficacy Disease-Modifying Therapies in People with Relapsing-Remitting Multiple Sclerosis: The Role of Risk Attitude in Treatment Decisions
    Maurino, Jorge
    Sotoca, Javier
    Sempere, Angel P.
    Brieva, Luis
    Lopez de Silanes, Carlos
    Caminero, Ana B.
    Terzaghi, Maria
    Gracia-Gil, Julia
    Saposnik, Gustavo
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2021, 14 (02): : 241 - 248
  • [2] Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis
    Merkel, B.
    Jokubaitis, V.
    Spelman, T.
    Horakova, D.
    Havrdova, E.
    Trojano, M.
    Izquierdo, G.
    Lugaresi, A.
    Prat, A.
    Girard, M.
    Duquette, P.
    Sola, P.
    Ferraro, D.
    Grammond, P.
    Hupperts, R.
    Bergamaschi, R.
    Alroughani, R.
    Boz, C.
    Terzi, M.
    Pucci, E.
    Van Pesch, V.
    Grand'Maison, F.
    Fernandez-Bolanos, R.
    Lechner-Scott, J.
    Spitaleri, D.
    Shaygannejad, V.
    Iuliano, G.
    Granella, F.
    Solaro, C.
    Prevost, J.
    Petersen, T.
    Olascoaga, J.
    Ramo-Tello, C.
    Verheul, F.
    McCombe, P.
    Slee, M.
    Sanchez-Menoyo, J. L.
    Cristiano, E.
    Ozakbas, S.
    Saladino, M. L.
    Ampapa, R.
    Vucic, S.
    Moore, F.
    Deri, N.
    Alkhaboori, J.
    Barnett, M.
    Van der Walt, A.
    Butzkueven, H.
    Kalincik, T.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 71 - 73
  • [3] TIMING OF HIGH-EFFICACY DISEASE MODIFYING THERAPIES FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Merkel, Bernd
    Jokubaitis, Vilija
    Spelman, Tim
    Lechner-Scott, Jeannette
    McCombe, Pamela
    Slee, Mark
    Vucic, Steve
    Skibina, Olga
    Barnett, Michael
    Hodgkinson, Suzanne
    Butzkueven, Helmut
    Kalincik, Tomas
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 (05):
  • [4] Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: A systematic comparison
    Freedman, Mark S.
    Hughes, Bruce
    Mikol, Daniel D.
    Bennett, Randy
    Cuffel, Brian
    Divan, Vamil
    LaVallee, Nicole
    Al-Sabbagh, Ahmad
    EUROPEAN NEUROLOGY, 2008, 60 (01) : 1 - 11
  • [5] Disease-modifying therapies in relapsing-remitting multiple sclerosis
    Gonzalez-Andrade, Fabricio
    Luis Alcaraz-Alvarez, Jose
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 365 - 373
  • [6] Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis
    Mariottini, Alice
    Nozzoli, Chiara
    Carli, Ilaria
    Landi, Filippo
    Gigli, Valentina
    Repice, Anna Maria
    Ipponi, Alessandra
    Cecchi, Michele
    Boncompagni, Riccardo
    Saccardi, Riccardo
    Massacesi, Luca
    NEUROLOGICAL SCIENCES, 2024, 45 (07) : 3379 - 3387
  • [7] Comparative safety of high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis
    Katarzyna Śladowska
    Paweł Kawalec
    Przemysław Holko
    Oktawia Osiecka
    Neurological Sciences, 2022, 43 (9) : 5479 - 5500
  • [8] EFFICACY AND SAFETY OF DISEASE-MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS: A SYSTEMATIC REVIEW
    Lingohr-Smith, M.
    Deitelzweig, C.
    Lin, G.
    Lin, J.
    VALUE IN HEALTH, 2021, 24 : S158 - S158
  • [9] Oral disease-modifying therapies for relapsing-remitting multiple sclerosis
    Thomas, Rachel Hutchins
    Wakefield, Richard A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (01) : 25 - 38
  • [10] Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches
    Grand'Maison, Francois
    Yeung, Michael
    Morrow, Sarah A.
    Lee, Liesly
    Emond, Francois
    Ward, Brian J.
    Laneuville, Pierre
    Schecter, Robyn
    NEURAL REGENERATION RESEARCH, 2018, 13 (11) : 1871 - 1874
12345